##  [Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS](/us-en/news/media-releases/novartis-data-show-gilenya-had-significantly-greater-patient-retention-compared-idmts-relapsing-remitting-ms-0 "Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS") 

  Jun 03, 2016